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Introduetion 
The concept of immunomodulation as an adjunct to 
cancer therapy is based on ample evidence that a variety 
of agents augment the immune reaction to unrelated an- 
tigens in experimental animals and increase their resis- 
tance to tumors. The ever-growing list of such agents 
includes viruses, bacteria, fungi, and their products 
(Ciba Foundation Symposium, 1973). Following the 
pioneering work of Math6 with BCG (Math~, 1971), in- 
vestigators have been very active in this field in recent 
years (Chedid et al., 1973; Lamensans et al., 1975; La- 
moureux et al., 1976; Laucius et al., 1974; Leclerc et al., 
1976; Mastrangelo et al., 1976; Old et al., 1959; Weiss 
et al., 1961; Zbar et al., 1970). Most, if not all of these 
studies, have been done with viable or killed microor- 
ganisms (Hersch et al., 1976; Israel, 1976; Pouillart et 
al., 1976), cell walls (Chedid et al., 1973; Gray et al., 
1975; Yamamura et al., 1976a; Zbar et al., 1972), or 
very complex fractions such as raethanol extract residue 
(MER) (Perloff et al., 1977; Yron et al., 1973) or inter- 
phase material (IPM) (Lamensans et al., 1975). 
Some organisms such as BCG and Corynebacterium 
parvum have been shown to be dramatically effective in 
certain experimental models, but investigators are well 
aware of the fact that they contain a great variety of 
heterogenous antigens, some of which might cross-react 
with host tissues (Borsos and Rapp, 1973; Bucana and 
Hanna, 1974; Vandenbark et al., 1975). They are also 
endowed with undesirable pharmacologic side effects 
(Werner et al., 1977). Consequently, current attempts at 
isolating chemically well-defined fractions from whole 
bacteria have been given a high priority, with the justifi- 
cation that they may lead to preparations that retain 
important therapeutic effects but with diminished or no 
toxicity. 
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In this paper, it is the aim of the authors to direct 
attention to newer compounds that have already been 
identified as the active molecules of the whole mycobac- 
terial cell, and whose synthesis has recently been ef- 
fected. Together with a discussion of other adjuvants, 
we advance the hypothesis that certain of these synthet- 
ic substances are able to regulate the immune response 
because of their structural analogy to molecules native 
to the parasitic agent or to the host. 
Synthetic Immunoadjuvants with Structural Analogy 
Related to Microorganisms 
Development of these synthetic compounds originated 
mainly through studies of mycobacteria, which were uti- 
lized extensively by several investigators because of their 
strong, multiple effects on the immune response. Al- 
though the capacity to immunize specifically against tu- 
berculous infection is restricted to certain strains of this 
organism, nonspecific resistance to infections (Blanden 
et al., 1969; Dubos and Schaedler, 1957; Howard et al., 
1959), as well as enhancement of tumor immunity (La- 
mensans et al., 1968; Laucius et al., 1974; Math+, 1971; 
Old et al., 1959; Zbar et al., 1971), has been elicited by 
a large variety of mycobacteria. As was shown by 
Freund, these organisms are also capable of inducing 
delayed hypersensitivity to many antigens when admin- 
istered with them in a water-in-oil emulsion, in addition 
to their property of markedly increasing humoral anti- 
body levels (Freund, 1956; White, 1976). Thus, a com- 
mon adjuvant unit was suggested, which was rather 
widely dispersed throughout the mycobacteria genus. 
However, the utilization of whole mycobacterial cells as 
adjuvants became restricted because of their multiple 
side effects, and because the nature of their immune 
modulation was unpredictable, e.g., tumor enhancement 
instead of rejection (Werner et al., 1977). Clinical appli- 
cation has also been severely limited by the requirement 
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for a nonmetabolizable oil as a component of Freund's 
complete adjuvant (FCA) (Holt, 1967). These realiza- 
tions have served as a continuing stimulus to fractionate 
mycobacterial cells and identify and synthesize the ac- 
tive, immunoregulating molecules devoid of toxicity and 
immunogenicity, such that they might be useful tools for 
clinical application. 
The difficult problem of determining the chemistry 
of fractions with adjuvant activity from mycobacteria 
had been pursued for many years, but only recently 
have the important, relevant structures been identified. 
Early investigations revealed that the whole organisms 
could be replaced by a wax, termed Wax D, which was 
extracted and solubilized in lipid solvents (Raffel, 1948; 
White et al., 1964), or by purified cell walls (Azuma et 
al., 1971). More recently, an important advance has 
been made in the identification of water-soluble fractions 
(Adam et al., 1972, 1973; Hiu, 1972; Migliore-Samour 
and Joll~s, 1972; Stewart-Tull et al., 1975). Thus, a 
preparation containing arabinogalactan linked to pepti- 
doglycan was obtained after lysozyme treatment of My- 
cobacterium smegmatis by Adam et al., and found capa- 
ble of substituting for whole mycobacterial cells in 
Freund's complete adjuvant (Adam et al., 1972, 1973; 
Hiu, 1972; Migliore-Samour and Joll~s, 1972; Stewart- 
Tull et al., 1975). In contrast to whole cells or to crude 
cell walls, this fraction, termed Water Soluble Adjuvant 
(WSA), did not induce side effects (Chedid et al., 1972) 
and was not arthritogenic, although it could induce de- 
layed hypersensitivity and, under some circumstances, 
autoimmune diseases (Lebar and Voisin, 1974; Toullet 
et al., 1974)• In vitro experiments have shown that WSA 
amplified the immune response to T-independent anti- 
gens, and that this activity might be exerted at the level of 
the macrophage (Modolell et al., 1974)• However, this 
adjuvant may have multiple effects in that WSA has 
been shown to be active in the mixed lymphocyte reac- 
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tion (Bona et al., 1974) and to be capable of restoring 
the immune response in mice depleted of antibody-form- 
ing cells (Liacopoulos et al., 1974)• In these instances, 
mediation may occur through the thymus-derived 
cell. 
Further chemical breakdown of WSA revealed that 
the minimal cell wall subunit capable of replacing whole 
mycobacterial cells in Freund's complete adjuvant was a 
monosaccharide tripeptide (Ellouz et al., 1974). A por- 
tion of the latter (N-acetyl muramyl-L-alanyl-D-isoglu- 
tamine, MDP) was subsequently synthesized and shown 
to be the minimal unit with immunoregulatory proper- 
ties (Adam et al., 1975; Ellouz et al., 1974; Kotani et al., 
1975a; Merser et al., 1975). The formula for WSA and 
MDP are shown in Figure 1, which depicts their rela- 
tionship to the mycobacterial cell wall skeleton and Wax 
D structure as stipulated by Lederer (Lederer, 1977; 
Lederer et al., 1975). 
In contrast to previous adjuvant fractions, MDP 
was found to be very active when injected in an aqueous 
medium with antigens (Audibert et al., 1977a, 1976). 
Moreover, its effects were demonstrable by several 
routes, including oral administration (Chedid et al., 
1976). Various aspects of the biological activity of MDP 
and its analogues have been reviewed recently (Chedid 
and Audibert, 1977; The Lancet, 1977) and its mecha- 
nisms of action studied in several systems (Damais et 
al., 1977, 1978; Juy and Chedid, 1975; Liacopoulos et 
al., 1974; Specter et al., 1977; Sugimoto et al., Yama- 
mura et al., 1976b). Thus, MDP has been shown to 
activate macrophages in vitro, enabling them to inhibit 
the growth of tumor target cells (Juy and Chedid, 1975). 
Oppenheim and Mizel have observed that MDP induces 
mitogenic activity in the supernatant fluids of mouse 
peritoneal exudate cells and human peripheral mononu- 
clear cells. This activity resulted when the cell popula- 
tion was enriched for adherent cells and is therefore like- 
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Fig. 1. Simplified scheme of the 
mycobacterial cell wall and its adjuvant- 
active derivatives wax D, water-soluble 
adjuvant (WSA), and N-acetylmuramyl- 
L-alanyl-D-isoglutamine (MDP). The WSA 
unit shown here has a molecular weight of 
about 2000. Myc: mycolie acid; 
L: lysozyme; according to E. Lederer (1977) 
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ly to be similar to lymphocyte-activating factor 'LAF', 
although the adherent cells contained some lymphocytes 
and therefore also may be making mitogenic factor (un- 
published results). 
Administration of MDP with SRBC enhances the 
titer of circulating antibodies by acting on T-lympho- 
cytes (L6wy et al., 1977). More recently, using trinitro- 
phenyl-ovalbumin and trinitrophenyl-keyhole limpet he- 
mocyanin as a carrier hapten system, it was observed 
that the effect was mediated by carrier-specific T-helper 
cells (Sugimoto et al.). 
Most of the data obtained when MDP was injected 
into saline, utilized systems concerned with humoral an- 
tibody production. When administered into Freund's in- 
complete adjuvant (FIA), MDP, like WSA, was found 
to induce delayed hypersensitivity (Azuma et al., 1976; 
Ellouz et al., 1974; Kotani et al., 1975b; Merser et al., 
1975; Tanaka et al., 1977b) and even autoimmune dis- 
eases (Nagai, 1976; Toullet et al., 1977). Its potency 
with respect to the latter was evidenced when it was 
shown that FIA containing MDP administered with a 
synthetic encephalitogenic peptide antigen was more 
powerful than FCA (Nagai, 1976). 
Recently, Yamamura has shown that allogeneic cell- 
mediated cytotoxicity was enhanced by MDP in vitro 
but not in vivo whereas a mycoloyl-MDP derivative was 
active in vivo (Yamamura et al., 1976b). In these studies 
the synthetic molecules were administered in an aqueous 
medium. These results argue favorably for the potential 
use of such agents in cell-mediated immunity and conse- 
quently in immunotherapy of cancer. 
Multiple analogues of MDP with minor modifica- 
tions are now being synthesized, and correlations be- 
tween biological activity and chemical structure are be- 
ginning to be made (Audibert el: al., 1977b; Chedid et 
al., 1976; Damais et al., 1978). To illustrate, certain de- 
rivatives, such as an MDP stereoisomer where D-alanine 
was substituted for the L form, were found capable of 
inhibiting the immune response, suggesting their possible 
use as immunosuppressants (Adam et al., 1976; Chedid 
et al., 1976). It is also of importance that certain of these 
synthetic analogues stimulated nonspecific resistance to 
infection (Chedid et al., 1977) and increased phagocyto- 
sis (carbon clearance) (Tanaka et al., 1977a). 
Although MDP was shown to be devoid of toxicity 
in normal or even adrenalectomized mice (Chedid et al., 
1977), it was surprisingly found that this molecule and 
some of the adjuvant active analogues induced a febrile 
response in rabbits (Kotani et al., 1976). 
It was also reported that MDP incubated with gran- 
ulocytes or monocytes recovered from humans or rab- 
bits induced the production of endogenous pyrogen in 
vitro. The same molecules used at high dosage levels 
were also capable of coagulating a limulus lysate (Di- 
narello et al., 1977). It must be noted, however, that two 
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analogues that have the same degree of adjuvant activity 
had a slight or even no detectable pyrogenicity under the 
same conditions (Dinarello et al., 1977). 
Synthetic Immunoadjuvants with Structural Analogies 
to Native Substances 
A second distinctive group of synthetic immunoregula- 
tory molecules were tested or produced initially because 
of their structural analogies with natural molecules of 
the host or the parasitic agent. For example, Munder 
et al. observed that, after stimulation by various adju- 
vants, an increased formation of lysolecithin by macro- 
phages occurred. Consequently, exogenous lysolecithin, 
as well as several analogues, were tested and shown to 
be active as adjuvants in vivo, augmenting antibody ti- 
ters to various antigens (Munder et al., 1976; Westphal 
et al., 1970). 
A somewhat similar rationale guided the investiga- 
tion a few years earlier of the effect of synthetic polynu- 
cleotides on the immune response (Johnson, 1976). Ini- 
tially, nucleic acids were explored as the possible endo- 
genous host mediator of the potent adjuvant action of 
the endotoxic lipopolysaccharides isolated from gram- 
negative bacteria (Merritt and Johnson, 1965). Thus, the 
cytotoxic action of the endotoxin in vivo was hypothe- 
sized to cause the release of cellular nucleic acids in the 
vicinity of immunocompetent cells, which were being 
called upon for a burst of nucleic acid synthesis as a 
result of concurrent antigen stimulation (Kind and John- 
son, 1959). The postulate that the released nucleic acids 
might serve as trephocytic molecules to help meet this 
demand and accentuate synthesis was supported by the 
subsequent demonstration that stimulation of the im- 
mune response to unrelated antigens was a property of 
both endogenous and exogenously derived nucleic acids, 
as well as of the low molecular weight breakdown products 
isolated following treatment of nucleic acids with nu- 
cleases (Johnson and Hoekstra, 1967; Merritt and John- 
son, 1965). Subsequently, Braun and his colleagues, 
guided both by their previous extensive studies showing 
oligonucleotides capable of stimulating division in bacte- 
rial cells, and by their postulate that mammalian anti- 
body synthesis might require endogenous stimulatory 
molecules of a similar nature (Braun and Firshein, 
1967), recognized and tested the potential of the newly 
developed (1965) synthetic polynucleotides. Their dem- 
onstration that polyinosinic, polycytidylic (poly I : C )  
and polyadenylic, polyuridyllc acid (poly A : U) com- 
plexes were capable of increasing the numbers of anti- 
body-forming cells 4 -5  fold caused interest to focus 
rapidly on these synthetic complexes because of their 
defined structure and ready availability (Braun and Na- 
kano, 1967). 
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Conversely, Hilleman et al. (1971), who were 
searching for the viral component responsible for the 
inducement of interferon in vivo, also explored the poly- 
nucleotides early as possible synthetic substances mim- 
icking parasitic activity. Their studies showed the dou- 
ble-stranded nucleic acids and their synthetic counter- 
part, poly I : C ,  to be convincingly active in this re- 
spect. 
The polynucleotide complexes have been found to be 
adjuvants in mice, rats, guinea pigs, and rabbits, and 
their activity has been established for a wide range of 
thymus-dependent antigens. The signal from the adju- 
vant is apparently received very rapidly by the host inas- 
much as the complexes are destroyed within 5-10 min 
by the nucleases in serum (Schmidtke and Johnson, 
1971). These adjuvants have proved to be very effective 
T-cell stimulants with respect to both T-helper (Cone 
and Johnson, 1971) and suppressor cells (Morris and 
Johnson, 1977), as well as to cytotoxic cells (Bick and 
Mtller, 1977). They show distinctive temporal require- 
ments in that injection of this adjuvant together with an 
antigen increases antibody synthesis (Schmidtke and 
Johnson, 1971). In contrast, injection of poly A : U 1 or 
2 days prior to injection causes the formation of sup- 
pressor cells with a resulting diminution of antibody 
synthesis (Morris and Johnson, 1977). Thus, these syn- 
thetic molecules can be considered true regulators of the 
immune system. Complexing of the base pairs has been 
shown to be a requirement in most instances (Schmidtke 
and Johnson, 1971), but when added to Freund's incom- 
plete adjuvant, poly U alone was capable of increasing 
delayed hypersensitivity in the guinea pig (Paterson and 
Drobish, 1975) and of sensitizing the rat for allergic en- 
cephalomyelitis. However, artifactually induced double- 
strandedness has not been ruled out in these instances 
(DeClercq and Merigan, 1969). 
Evidence has been gained that poly A : U functions 
as an adjuvant by causing T-lymphocytes to hasten 
their secretion of T-helper factors (Bick and Johnson, 
1977). Such soluble helper factors secreted under the 
influence of poly A : U have been shown to increase the 
number of antibody-forming cells in the spleen, and 
were active in restoring the deficient immune response of 
aging mice (Han and Johnson, 1976) and preventing the 
development of tolerance in normal mice (Fessia et al., 
1977). In addition, poly A : U has been shown to in- 
crease markedly the maturation of the immune system 
in the neonatal mouse (Han and Johnson, 1976). 
Little, if any, toxicity has been displayed by poly 
A : U. On the other hand, poly I : C has proven to be 
toxic to intestinal tissue, pyrogenic, and lethal for mice, 
and induce hemorrhagic necrosis in kidneys (Han et al., 
1973; Philips et al., 1971). 
Recently, it has been shown that human peripheral 
blood leukocytes (PBL) double the synthesis of immu- 
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noglobulin when stimulated by poly A :U. PBL from 
patients with acquired agammaglobulinemia similarly 
showed elevated Ig synthesis under the influence of po- 
lynucleotides. However, such cells from patients with 
congenital agammaglobulinemia could not be elevated 
in their synthetic capacity by poly A : U (Lederman et 
al., 1977). 
Both polynucleotide complexes have been shown to 
be effective stimulants of the immune system against 
certain tumors (Johnson, 1976). However, the lack of 
toxicity of the poly A : U complex may be an important 
determinant of priority in this respect. Field trials are 
under way in human beings to measure the effectiveness 
of poly A : U on the immune response of tumor-bearing 
patients as well as of patients who have undergone 
tumor removal by surgery (Lacour et al., 1974). 
Synthetic Drugs as Immunoadjuvants 
Within the past decade, other synthetic compounds have 
been shown to stimulate immunity. However, in contrast 
to MDP, its analogues, and the polynucleotides, these 
molecules were tested initially because of their various 
pharmacologic activities rather than being derived from 
active microorganisms. For example, Mayer and Fink 
(Mayer and Fink, 1970) have shown that bis-(diethyl- 
amino-ethoxy)-fluoren-9-one (tilorone) induced the im- 
munoregulatory molecule, endogenous serum interferon, 
even on oral administration. Further experimentation 
has shown that tilorone is capable of enhancing anti- 
body responses to sheep red blood cells (Diamantstein, 
1973) and of suppressing delayed hypersensitivities 
(Megel et al., 1974). 
In addition, another synthetic compound of low mo- 
lecular weight, tetramisole, was shown by Renoux and 
Renoux in 1971 to augment the protective effect of a 
Brucella vaccine in mice (Renoux and Renoux, 1971). 
This compound had been available several years pre- 
viously as an antihelminthic drug. Levamisole hydro- 
chloride is the levarotory enantiomer of tetramisole and 
appears to have similar effects on the immune system 
(Renoux and Renoux, 1971). This observation 
prompted intensive investigative efforts, both by immu- 
nologists and clinicians, resulting in more than 400 pa- 
pers being published in this short period of time (Sy- 
moens, 1976; Symoens and Rosenthal, 1977). 
The cumulative evidence from studies on isolated 
cells, experimental animals, healthy volunteers, and pa- 
tients suggests that levamisole restores to normal the 
functions of phagocytosis and T-lymphocytes in immu- 
nodeficient hosts. Although this compound has been 
studied extensively by various investigators for its effect 
in oncologic diseases, there still exist many conflicting 
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data in the literature. A very complete review of this 
subject has been published by Symoens and Rosenthal 
(1977). In addition, Oettgen et ad. have discussed levam- 
isole thoroughly in the recent Symposium on Immuno- 
therapy of Malignant Disease (Oettgen et al., 1976). 
The trend toward synthetic adjuvants is emphasized 
further by the recent studies of 4-imino-l.3-diazabi- 
cyclo-(3.1.O)-hexan-2-on, Boehringer Mannheim 
(BM06002), by Micksche (Micksche et al., 1977). This 
adjuvant has been reported to be active for both hu- 
moral and cell-mediated immune reactions in animal 
models, and to stimulate immune reactions in man. 
Discussion 
The nature of adjuvant material has long been consid- 
ered to be foreign, aggressive, or insulting to the host. 
Consequently, it was expected that only complex, insol- 
uble, undegradable materials were capable of enhancing 
the immune response by nonspecific mechanisms. Since 
Freund's complete adjuvant consistently has been docu- 
mented as the most potent agent in this respect, it was 
postulated that whole mycobacterial cells or cell walls 
were required for its manifestation. The discovery that 
Wax D, a well-defined material, could substitute for the 
whole cell did not alter this view considerably, inasmuch 
as Wax D contains mycolic acid, which represents a 
unique mycobacterial constituent and renders this mate- 
rial difficult to be disposed by the host. Even the discov- 
ery of the activity of WSA and the native monosaccha- 
ride tripeptide subunit was consistent with the require- 
ment for a foreign structure, since diaminopimelic acid 
(DAP), D-isoglutamine, and N-acetylmuramic acid do 
not exist in eukaryotes. However, with the knowledge 
that removal of DAP still did not abolish the adjuvant 
activity, it became more apparent that extremely small 
and simple molecules with minimal differences from the 
host's own structures were sufficient for adjuvanticity. 
The fact that regulation of the immune response now 
can be achieved with such small peptides raises the 
question as to whether these molecules function by vir- 
tue of possessing structures similar to those existing in 
the host. One might boldly pose the question "Does 
MDP and its analogues represent man's synthetic ver- 
sion of a natural lymphokine?" (Barksdale and Kim, 
1977). 
It is important to recognize in this respect that lym- 
phokine structures are unknown and that only a few 
immunoregulatory molecules of the host other than im- 
munoglobulin, thymic serum factors, and thymosin 
alpha 1 have been sequenced. The latter two were 
recently also synthesized. As a matter of fact, the syn- 
thesis of analogues of bacterial products with immuno- 
logic activity may represent an easier approach to the 
223 
acquisition of knowledge of natural structures. It is of 
interest that o-isoglutamine, which is essential for the 
activity of MDP, is not hydrolyzable by enzymes of 
mammalian hosts and thus cannot be degraded. Substi- 
tution of the L-isomer at this point results in an inactive 
adjuvant. One might then speculate that the nonde- 
gradable synthetic product may be a distinct asset as 
compared with the natural mediators, which probably 
have short biological half-lives. 
We attach conceptual importance to the omission of 
the word 'immunoadjuvant' from our title. It expresses 
our feeling that a new era in studies of adjuvants has 
dawned in which these substances are recognized as 
having a much broader regulatory activity in inducing 
suppression as well as in enhancing the immune re- 
sponse (Schwab, 1975). It is of interest in this respect 
that in his recent review, Schwab stated that "Almost 
every material having adjuvant activity can also be dem- 
onstrated to suppress the immune response with appro- 
priate manipulation of timing, dose and selection of an- 
tigen. The greater significance of these agents may be as 
immunosuppressants." Several adjuvants have now 
been demonstrated to be active immunosuppressive 
agents in animals at microgram levels as compared with 
the milligram doses required with cancer therapeutic 
drugs. Whereas all known bacterial adjuvants such as 
BCG and C. parvum, etc., have considerable antigenic 
diversity, the functionally pure fractions now available 
and described herein should provide distinctive probes 
for definitive studies of immunoregulatory mecha- 
nisms. 
Experimental analysis of the structural control of 
immunogenicity has shown that the humoral response to 
DNP-oligolysines was dependent on the kind of myco- 
bacteria used in FCA (Stupp et al., 1971). Under certain 
well-defined conditions, the magnitude of the antibody 
response was independent of the PLL gene status of the 
guinea pigs, but was related to the type of mycobacteria 
used (HaTRv instead of M. butyricum). Similarly, Nagai 
(1976), using an analogue shorter than the nonapeptide 
encephalitogen antigen, has presented evidence that 
MDP selectively induced this autoimmune disease, 
whereas FCA with whole mycobacteria could not. 
Therefore, such well-defined synthetic adjuvants should 
also permit a more precise appraisal of the genetics of 
the immune response. Up to the present time, these stud- 
ies have been undertaken necessarily with very complex 
adjuvant materials. 
The addition to tumor therapy of immunoregulating 
substances such as those reviewed herein may be advo- 
cated for multiple reasons. For example: 
(a) enhancement of specific immunization by tumor 
antigens, 
(b) enhancement of nonspecific immunity active 
against tumors, 
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(C) use of  the immunosuppressive capaci ty  of  certain 
analogues to reduce tumor-blocking or tumor-enhancing 
antibodies, and 
(d) restorat ion of  immunocompetence  following a 
deficiency induced by  the cancer itself or by  cancer  che- 
motherapy.  
Man  has the habit  of  interpreting Nature  in ways  
more difficult than she intended. Fo r  a long time, there 
have been conceptual  differences between chemotherapy 
and immunotherapy,  sometimes to the point  of  the two 
being in opposition. Yet it must  be recalled that  cancer 
chemotherapy has rendered available for decades sever- 
al synthetic cytostatic compounds which were also im- 
munosuppressive as recently reviewed in detail (Schwab, 
1975). The gap existing between chemical and immuno- 
logic approaches  to tumor  therapy also appears  to be 
bridged by the availability of  the synthetic compounds  
emphasized herein that  represent analogues of  natural  
structures existing in the host  or parasi te  and that  are 
capable of  regulating the immune response. The ratio- 
nale for use of  polynucleotides as adjuvants  has been 
their relationship to natural  products  existing in the host 
or in viruses. Similarly, it has been suggested by  Barks- 
dale (Barksdale and Kim, 1977) that  M D P  could "do its 
job  because it mimics a regulator molecule of  the im- 
mune system." Whether  such is the case remains to be 
demonstra ted;  however, the recognition of  the emer- 
gence of  low molecular  weight monosacchar ide  pep- 
tides, representing an ext raordinary  small unit capable  
of  replacing mycobac ter ia  in Freund ' s  adjuvant,  should 
help to establish an impor tant  bridging relationship be- 
tween chemical and immunologic tumor  therapy.  
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